[Therapy of migraine. Clinical experience with Migraeflux, a new migraine drug].

The new migraine preparation Migraeflux has been subjected to clinical trial in a double-blind cross-over study in 32 single tests. Compared with other products, the 2-phase-preparation Migraeflux is distinguished--due to its antihistaminic ingredient--by the capacity of preventing in 2/3 of the cases the formation of a migraine attack if applied soon during the prodromal phase. If the attack is not prevented, the intensity of pain is lessened in 70% of the remaining cases and the duration of attack is markedly reduced. The preparation proved to be tolerated very well.

RCT Entities:   Population Interventions Outcomes